Opus Genetics, Inc.
Phentolamine Ophthalmic Solution 0.75%
presbyopia
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for Phentolamine Ophthalmic Solution 0.75% in presbyopia are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of 2026.”